Pola-R-GemOx Regimen Extended Survival for Lymphoma Patients
The POLARGO clinical trial found that a new treatment approach significantly improved outcomes for those with relapsed lymphoma.
Updated on Oct. 10, 2026 in Cancer
Live Poll
Should medical researchers prioritize testing new combination drug therapies for difficult-to-treat cancer patients?
The POLARGO trial has demonstrated that the Pola-R-GemOx regimen improves median overall survival for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients receiving this treatment saw median survival reach 19.5 months compared to 12.5 months for those on the standard R-GemOx regimen.
Why it matters
Patients ineligible for transplants who face relapsed or refractory DLBCL have historically faced poor prognoses and a lack of viable treatment options. This study highlights a potential therapeutic shift to improve survival rates in a population with significant unmet medical needs.
The POLARGO trial involved 255 adults across 64 sites, showing a hazard ratio for death of 0.60. While the complete response rate reached 40.3%, researchers noted fatal adverse events occurred in 12% of the treatment group.
The players
European Hematology Association
This is a professional medical organization that promotes the study and clinical practice of hematology through congresses and research dissemination.
Journal of Clinical Oncology
This is a peer-reviewed medical journal that publishes significant clinical research regarding the diagnosis and treatment of cancer.
The details
Investigators assigned 255 adult patients in a 1:1 ratio to receive either Pola-R-GemOx or R-GemOx every 21 days for up to 8 cycles. The regimen notably extended median progression-free survival to 7.4 months, though 57.0% of patients in the treatment arm experienced peripheral neuropathy.
Timeline
The POLARGO trial was presented at the European Hematology Association congress in 2025.
The findings were published in the Journal of Clinical Oncology in 2026.
The Big Picture
The POLARGO trial underscores a growing trend toward testing combination therapies for patients who cannot undergo traditional stem cell transplants. By demonstrating a 40% reduction in the risk of death, these results establish a new clinical benchmark for refractory lymphoma treatment.
This development offers a potential new treatment pathway for patients previously considered transplant-ineligible, though it carries a risk of significant side effects like peripheral neuropathy. Patients should discuss these findings and potential risks with their oncology teams to determine if this regimen is appropriate for their specific clinical situation.
The takeaway
These findings represent a measurable improvement in survival outcomes for a historically difficult-to-treat patient population. Healthcare providers may use this regimen as a new standard for managing refractory lymphoma in individuals who cannot undergo intensive transplant procedures.
Further reading
Learn more about advancements in Cancer research and treatments.
Source note: This article includes information reported by Ajmc.
Live Poll
Should medical researchers prioritize testing new combination drug therapies for difficult-to-treat cancer patients?
